Shows cost-effectiveness of molecular-integrated profile in high intermediate risk endometrial cancer, indicating better treatment options.
Individualised adjuvant treatment based on a molecular-integrated-profile was more cost-effective than standard VBT for patients with HIR-EC. These results further support the implementation of the molecular-integrated-profile in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Heerik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: